Taiyen Biotech Co Ltd

Taiyen Biotech maintains a strong liquidity position with a current ratio of 2.87, indicating the company can easily cover its short-term liabilities with its short-term assets. The company's cash and equivalents amount to TWD 705.15 million, which provides a buffer against short-term obligations. The liquidity FPT (free cash flow to total liabilities) is not explicitly provided, but the low liquidity risk assessment suggests the company is not under immediate pressure to raise additional capital. Profitability metrics show that Taiyen Biotech is performing in line with industry expectations. The company's return on equity (ROE) is 5.87%, and its return on assets (ROA) is 4.84%. These figures are consistent with the industry's preferred metrics for evaluating performance in the food processing sector. The company's operating margin is 13.72% (calculated as operating income of TWD 453.60 million divided by revenue of TWD 3.31 billion), which is a strong indicator of efficient operations. Geographically, Taiyen Biotech's revenue is concentrated in a single market, as no segment or geographic breakdown is provided in the available data. This lack of diversification could expose the company to regional economic fluctuations. The absence of disclosed segments also limits the ability to assess the performance of individual product lines or geographic regions. The company's growth trajectory appears stable, with no significant changes in revenue or earnings reported in the latest financial data. The operating cash flow of TWD 432.05 million and free cash flow of TWD 66.54 million suggest the company is generating sufficient cash to support operations and potentially fund future growth. However, the capital expenditure of TWD -300.16 million indicates that the company is not currently investing heavily in new projects or infrastructure. Risk factors for Taiyen Biotech are currently low, with no immediate filing-based liquidity or dilution flags detected. The company's debt-to-equity ratio is 0.02, indicating a conservative capital structure with minimal reliance on debt financing. The low dilution risk suggests that the company is not likely to issue additional shares in the near term, preserving shareholder value. Recent events related to Taiyen Biotech include the latest actual EPS of 1.34 TWD, as reported by analysts. No significant filings or transcripts have been disclosed in the available data, which limits the ability to assess recent strategic developments or management commentary.